{"id":77710,"date":"2026-02-24T00:05:06","date_gmt":"2026-02-24T00:05:06","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/"},"modified":"2026-02-24T00:05:06","modified_gmt":"2026-02-24T00:05:06","slug":"palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/","title":{"rendered":"Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN&#x2122; 3.9% Rapamycin Anhydrous Gel (QTORIN&#x2122; rapamycin) in Microcystic Lymphatic Malformations\u00a0"},"content":{"rendered":"<div>\n<p><em>Webcast conference call to take place tomorrow, Tuesday, February 24, 2026, at 8:00am ET<\/em><\/p>\n<p align=\"justify\">WAYNE, Pa., Feb.  23, 2026  (GLOBE NEWSWIRE) &#8212; (Nasdaq: PVLA)\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tZRZE7X32TJUIT12Bs2G9ejJbXVF3DXTlNg-_2Ju6ych5i1ZoHsHznwg6pVyTBrWugziAR-4pimN6JHtpxjB1z0IwX3b9iMQbku1mrbVGaQ=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>Palvella Therapeutics<\/u>, Inc.<\/a> (Palvella or \u201cthe Company\u201d), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will host a conference call and webcast tomorrow, Tuesday, February 24, 2026, at 8:00am ET to discuss topline results from the Phase 3 SELVA clinical trial assessing the efficacy and safety of QTORIN&#x2122; 3.9% rapamycin anhydrous gel (QTORIN&#x2122; rapamycin) for the treatment of microcystic lymphatic malformations. The Company plans to issue a press release sharing the topline results at approximately 6:30am ET tomorrow, prior to the start of the call.<\/p>\n<p><strong>Conference Call <\/strong><\/p>\n<p align=\"justify\">To access the live webcast of the call with slides, please click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Qbxv9hCid3xTxwot1iJ1pB4t__UzcJK_u0C_A6_-bLNKaXxm-Lw1EbCcBsqBinfLT_M136eAHaecNIFVh4Ndk-OI3_lN-EK6k_lLW11e8Tg=\" rel=\"nofollow\" target=\"_blank\" title=\"here\">here<\/a> or visit the &#8220;Events &amp; Presentations&#8221; section of Palvella\u2019s website. To access the call by phone, please use this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WZwtwVPZwSg_1J28SlgNHV8aryCZr6UHkh7FjTmCumaTV2CSlJffCqz-zt8282E6q_Omk3ZY3Z1LT8dxapkA4tOYWJNnHF6tBP20rAPf7Ve5eMT58NADeIryy-sN1KSb8KGsLATA0dTVZtT3SouWLHhIEY_gW3nKP7iXKqTzAyU=\" rel=\"nofollow\" target=\"_blank\" title=\"registration link\">registration link<\/a>, and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the &#8220;Events &amp; Presentations&#8221; section of the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hYIXpIiiks-WKERHK8c3rXumJWqotOKFMitkbNWAy8ZdK_0UDOAVzEMfIQFIzvGRZW0ndRPVpPdj5h3wunH2COXgLJldDhYdbVQ7rsoRT5Y=\" rel=\"nofollow\" target=\"_blank\" title=\"www.palvellatx.com\">www.palvellatx.com<\/a>.<\/p>\n<p align=\"justify\"><strong>About Palvella Therapeutics<\/strong><\/p>\n<p align=\"justify\">Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN&#x2122; platform, with an initial focus on serious, rare skin diseases, many of which are lifelong in nature. Palvella\u2019s lead product candidate, QTORIN&#x2122; 3.9% rapamycin anhydrous gel (QTORIN&#x2122; rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella\u2019s second product candidate, QTORIN&#x2122; pitavastatin, is currently being developed for the topical treatment of disseminated superficial actinic porokeratosis. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hYIXpIiiks-WKERHK8c3rR9KlKq7baanCdUUga14YZFVddP1qxazFsEoyEqOQyLquLFaxXkJ3GZIuhbNwmheZT978wZVTX_tgoLhknQrnYwZJlWOJKpVyhxFSS-ZRHc1-NIva_SmdpCSJQql17al4qF3Ub8X2lAUXE49_eHbKoX64eGCbJUwJD2PldBxGxnnncaUuoekIzjGHGTSxKffYZPYT2jmwj_6GqJFTDG4NB1hLSvv8Cn9FOreRwemb378CtJjoKppfEvJs4Nk30tZyg==\" rel=\"nofollow\" target=\"_blank\" title=\"www.palvellatx.com\">www.palvellatx.com<\/a>\u00a0or follow Palvella on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uTmNrfU6DVfJievxAir9WfVESNijjkFVH5Qnh7ZZo_oz0XcZFCO9HqSQ9uKVj-HSH4tgrFSGAidtdphYcYJ3JVPQ6nswXbRE8mQ1E01OXD6oxh0w39WDCUBBr63OL4Ebf9AIgFgLjghBIHx6550-fBpilkk3yF9yBpYearhPGfGDgSzeGz8nUpXYBh7s_qNS6-mTCfm0hutsjKYbfyvlFrNtG771p2FbKjcJij5P00qxS0U4NGmfFSdUhX__83ZQoEHBbVOWpJQSG4L44kkUpw==\" rel=\"nofollow\" target=\"_blank\" title=\"LinkedIn\">LinkedIn<\/a>\u00a0or\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7gS9T5t15vJ9-qcqnoX5ZLlz4unJqbLkhe0C0xUgrfLDo6F3AUTKyUrtvwplFp2iL9EYBbHYHpwuGRFW0n6TebN9gc-NwB1P8uQA3i0v4ndZo57mM2ZPRpUZKD7gNuJxS25_OjyIS1jqEpKpYWskQoTn2J_OxPuGkk8WMTI5D3Q8T6oaxMYRUyEpXuvgoiNtx3W8t8S7ko0WySGkczA-dw==\" rel=\"nofollow\" target=\"_blank\" title=\"X\">X<\/a>\u00a0(formerly known as Twitter).<\/p>\n<p align=\"justify\">QTORIN&#x2122; rapamycin and QTORIN&#x2122; pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.<\/p>\n<p><strong>Contact\u00a0Information<\/strong><\/p>\n<p>Investors<br \/>Wesley H. Kaupinen<br \/>Founder and CEO, Palvella Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m0Mr-lZZgNJT6laZD_v5cPyHMQBBTtrsQ5S0rsAdA0Wc76ek_33BiY2wc-NAUhHtiNI2zphyZ6ewLJz8UEYdte7o1wRdRcjX09-joGXmycOnW-Tz4dq0EVycIl9z8e2e\" rel=\"nofollow\" target=\"_blank\" title=\"wes.kaupinen@palvellatx.com\">wes.kaupinen@palvellatx.com<\/a><\/p>\n<p>Media<br \/>Marcy Nanus<br \/>Managing Partner, Trilon Advisors LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AYeno3AZYbal0IuGYbBgPIhD9YrWOMLhny9kdcDju1e2bGzpcfNZnQVuBvLy2S2MrqPbbWZhP_Amn3Je1KGjih9mhWFEVmtnTvbMyhVBZ9FhtIjcccr7KrLb3JWBMVG9LnPshQDgLFlhK5xI6SJdeA==\" rel=\"nofollow\" target=\"_blank\" title=\"mnanus@trilonadvisors.com\">mnanus@trilonadvisors.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjQ3ZGRjZTEtZDk1OS00ODc1LTk4ZDItNGRlNTg2NWRlMWY4LTExMzQ3MzQtMjAyNi0wMi0yMy1lbg==\/tiny\/Palvella-Therapeutics-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Webcast conference call to take place tomorrow, Tuesday, February 24, 2026, at 8:00am ET WAYNE, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) &#8212; (Nasdaq: PVLA)\u00a0Palvella Therapeutics, Inc. (Palvella or \u201cthe Company\u201d), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which [&#8230;]\n","protected":false},"author":1,"featured_media":77711,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-77710","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN&#x2122; 3.9% Rapamycin Anhydrous Gel (QTORIN&#x2122; rapamycin) in Microcystic Lymphatic Malformations\u00a0 - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN&#x2122; 3.9% Rapamycin Anhydrous Gel (QTORIN&#x2122; rapamycin) in Microcystic Lymphatic Malformations\u00a0\" \/>\n<meta property=\"og:description\" content=\"Webcast conference call to take place tomorrow, Tuesday, February 24, 2026, at 8:00am ET WAYNE, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) &#8212; (Nasdaq: P\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T00:05:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/02\/Palvella-Therapeutics-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN&#x2122; 3.9% Rapamycin Anhydrous Gel (QTORIN&#x2122; rapamycin) in Microcystic Lymphatic Malformations\u00a0\",\"datePublished\":\"2026-02-24T00:05:06+00:00\",\"dateModified\":\"2026-02-24T00:05:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/\"},\"wordCount\":447,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/\",\"name\":\"Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN&#x2122; 3.9% Rapamycin Anhydrous Gel (QTORIN&#x2122; rapamycin) in Microcystic Lymphatic Malformations\u00a0 - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-02-24T00:05:06+00:00\",\"dateModified\":\"2026-02-24T00:05:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN&#x2122; 3.9% Rapamycin Anhydrous Gel (QTORIN&#x2122; rapamycin) in Microcystic Lymphatic Malformations\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN&#x2122; 3.9% Rapamycin Anhydrous Gel (QTORIN&#x2122; rapamycin) in Microcystic Lymphatic Malformations\u00a0 - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/","og_locale":"en_US","og_type":"article","og_title":"Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN&#x2122; 3.9% Rapamycin Anhydrous Gel (QTORIN&#x2122; rapamycin) in Microcystic Lymphatic Malformations\u00a0","og_description":"Webcast conference call to take place tomorrow, Tuesday, February 24, 2026, at 8:00am ET WAYNE, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) &#8212; (Nasdaq: P","og_url":"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-02-24T00:05:06+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/02\/Palvella-Therapeutics-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN&#x2122; 3.9% Rapamycin Anhydrous Gel (QTORIN&#x2122; rapamycin) in Microcystic Lymphatic Malformations\u00a0","datePublished":"2026-02-24T00:05:06+00:00","dateModified":"2026-02-24T00:05:06+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/"},"wordCount":447,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/","url":"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/","name":"Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN&#x2122; 3.9% Rapamycin Anhydrous Gel (QTORIN&#x2122; rapamycin) in Microcystic Lymphatic Malformations\u00a0 - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-02-24T00:05:06+00:00","dateModified":"2026-02-24T00:05:06+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-in-microcystic-lym\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN&#x2122; 3.9% Rapamycin Anhydrous Gel (QTORIN&#x2122; rapamycin) in Microcystic Lymphatic Malformations\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/77710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=77710"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/77710\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/77711"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=77710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=77710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=77710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}